We are live on ! Find out more
BJCM

Blue Jay Capital Management Portfolio holdings

AUM $147M
1-Year Est. Return 64.18%
This Fund
S&P 500
This Quarter Est. Return
+15.38%
1 Year Est. Return
+64.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$203M
AUM Growth
+$37.7M
Cap. Flow
+$16.9M
Cap. Flow %
8.33%
Top 10 Hldgs %
53.62%
Holding
27
New
12
Increased
1
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$13.1M
2
GMED icon
Globus Medical
GMED
+$10.9M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.34M
4
NVRO
NEVRO CORP.
NVRO
+$9.06M
5
NUVA
NuVasive, Inc.
NUVA
+$8.95M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$11M
2
HOLX
Hologic
HOLX
+$11M
3
LH icon
Labcorp
LH
+$10.9M
4
BSX icon
Boston Scientific
BSX
+$10.8M
5
SHPG
Shire pic
SHPG
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 78.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXN
26
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-90,134
Closed -$11M
SHPG
27
DELISTED
Shire pic
SHPG
– –
-62,500
Closed -$10.6M
1
2

Similar funds

BCM
Breithorn Capital Management New York $141M AUM 41.82% 1-Year Est. Return
RJA
Robshaw & Julian Associates Williamsville, New York $140M AUM 13.69% 1-Year Est. Return
RP
Ridgegate Proprietary Sydney, Australia $154M AUM 25.47% 1-Year Est. Return
ACPVT
ABS Capital Partners V Trust Baltimore, Maryland $123M AUM
SFA
Staton Financial Advisors Charlotte, North Carolina $118M AUM 11.07% 1-Year Est. Return
KL
Kinsight LLC Birmingham, Alabama $176M AUM 17.21% 1-Year Est. Return
KFS
Kissinger Financial Services Hunt Valley, Maryland $100M AUM 6.22% 1-Year Est. Return
FHC
First Houston Capital Houston, Texas $100M AUM 23.45% 1-Year Est. Return

Blue Jay Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, Blue Jay Capital Management held 27 positions worth $203M, up 23% from $166M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Blue Jay Capital Management deployed $16.9M of net new capital in Q1 2017, opening 12 new positions and adding to 1 existing holding. Its largest new stake was Biogen: 46,320 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 79% a quarter earlier.

On the sell side, the largest reduction was Clovis Oncology, Inc., an estimated $9.06M trimmed.

  • Blue Jay Capital Management's largest Q1 2017 buy was Biogen: 46,320 shares worth $12.7M.
  • Blue Jay Capital Management added most to Bristol-Myers Squibb in Q1 2017, an estimated $1.65M increase.
  • Blue Jay Capital Management's biggest Q1 2017 reduction was Clovis Oncology, Inc., cutting an estimated $9.06M.
  • Blue Jay Capital Management fully exited Alexion Pharmaceuticals in Q1 2017, selling an estimated $11M.
  • Blue Jay Capital Management's ten largest holdings make up 54% of its $203M portfolio in Q1 2017.
  • Blue Jay Capital Management opened 12 new positions and closed 6 in Q1 2017.
  • Blue Jay Capital Management's portfolio value rose 23% quarter-over-quarter to $203M.

Based on Blue Jay Capital Management's 13F filing for Q1 2017, filed 12 May 2017.